Major Outcomes
Rick Doblin
- The participants recognized the worldwide absence of any systematized
pharmacologically-assisted psychotherapy research program involving both
pre-clinical and clinical investigations and supported increasing the
research effort.
- Psychiatrists from the US and the USSR agreed to begin designing a
protocol for the investigation of the use of MDMA in the psychotherapeutic
treatment of patients with terminal illness. Their intention is to conduct
the identical experiment in both countries in order to increase
statistical validity and generalizability of the results.
- US neurotoxicity researchers tentatively agreed that the neurotoxic
risk to patients with terminal illness is balanced by potential
psychotherapeutic benefits. If the protocol is rigorously designed to
provide additional data about both neurotoxic risk and therapeutic
efficacy, they may support the protocol before the FDA.
- MAPS agreed to help assemble a small group of distinguished U.S.
scientists and researchers to review, critique and endorse protocols prior
to FDA submission.
